Skip to main content
BDX logo

BDX · Becton Dickinson & Co

Track BDX — free
$215.42 -1.05 (-0.49%) At close · Nov 17
Market Cap
$58.68B
Shares
272.39M
Volume · Nov 17 2.31M Avg daily vol (3M) 1.81M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$215.42 Open$215.04 Day$214.05–216.98 Since split$140.71–218.03 Avg vol 30d1.8M Short int8.1M · 3.0% of shares · 5.2d Short vol58% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Aug 6

The closing range begins at the captured split on Feb 10, 2026.

Up next

Feb 8, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 5
Earnings call
Q4 EPS jumps 27.3% to $4.15

Becton Dickinson & Co reported fourth-quarter revenue of $5.3 billion, up 5.6%, and adjusted EPS of $4.15, up 27.3%. Guidance calls for low single-digit revenue growth and adjusted EPS of $13.10 to $13.30.

3 source passages
Earlier today, we reported strong Q4 results, with revenue of $5.3 billion, up 5.6%, and 27.3% growth in adjusted EPS to $4.15. Starting with revenue, we expect low single-digit growth for the full year. Adjusted EPS is expected to be in a range of $13.10 to $13.30. Open the document at this passage
Nov 5
Current report 8-K
Fiscal 2027 EPS guidance issued after 4.9% revenue growth

Becton, Dickinson and Company reported FY26 revenue of $19.5 billion, up 4.9%, adjusted diluted EPS of $12.70, and fiscal 2027 adjusted diluted EPS guidance of $13.10 to $13.30.

Financial results
5 source passages
BD (Becton, Dickinson and Company) •FY26 revenue of $19.5 billion increased 4.9% as reported, 3.9% FXN •FY26 GAAP and adjusted diluted EPS of $5.06 and $12.70, respectively The company provides the following guidance with respect to fiscal 2027. Adjusted Diluted Earnings per Share from Continuing Operations | 12.70 | $13.10 to $13.30 Open the document at this passage
Aug 6
Quarterly report 10-Q FY2026 Q3, ended Jun 30
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $4.98B ▲ 5.4% Net income $377M ▼ 34.3% Diluted EPS $1.37 ▼ 31.5%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$22.41B
Trailing 12 months
Net income (TTM)
$941.00M
Trailing 12 months
Revenue growth YoY
+5.4%
Year over year
Operating margin
10.3%
Trailing 12 months
P / E (TTM)
107.6
Trailing earnings · reciprocal yield 0.9%
FCF yield
—
TTM · current market cap
Return on invested capital
5.0%
Trailing 12 months
Net cash
−$16.10B
Latest balance sheet
Dividend yield
1.8%
Trailing 12 months
Shares change YoY
-4.2%
Year over year · fewer shares
Price change (1Y)
—
Trailing year
Short interest
3.0%
Latest settlement · 5.2 days to cover
View all 125 metrics

AI Brief

Q4 FY26 earnings call · Nov 5, 2026
Q4 FY26

TL;DR. BD delivered strong FY26 growth, Q4 margin expansion and 42% free-cash-flow growth, while returning $3.6 billion to shareholders. FY27 guidance calls for low single-digit revenue growth, with Alaris and currency headwinds and roughly flat operating margin.

Bullish
  • + Q4 revenue grew 5.6% to $5.3 billion and adjusted EPS grew 27.3% to $4.15.
  • + FY26 revenue grew 3.9% to $19.5 billion and adjusted EPS grew 6.7% to $12.70.
  • + Q4 adjusted gross margin was 56.8% and adjusted operating margin expanded to 28.6%.
  • + FY26 free cash flow increased 42% to $2.9 billion and conversion rose to 74% including separation costs.
  • + BD returned $3.6 billion to shareholders in FY26, including approximately $2.4 billion of share repurchases and $1.2 billion in dividends.
  • + The Liberty tip stent graft received FDA approval in Q4 and is seeing strong customer interest.
Bearish
  • − FY27 revenue guidance is for low single-digit growth.
  • − The Alaris capital comparison creates approximately 200 basis points of pressure in FY27.
  • − Currency is expected to be a headwind of about 70 basis points to FY27 revenue growth.
  • − FY27 adjusted operating margin is expected to be roughly flat year over year.
  • − FY26 adjusted operating margin declined 20 basis points, and tariffs had a 90 basis-point impact.
  • − Vaccines declined about 11% in Q4.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Moderate
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +27%
above
Price vs 50-day avg +12%
above
RSI (14) 70
neutral
MACD trend Positive
52-week position 97%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +11%
trailing
6-month return +45%
trailing
YTD return +41%
this year
Relative strength +48%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $192 › 200d $169 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +164 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.98% of shares out · ▼ -9.0% MoM · 5.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1,501 holders — near 3-yr low, contrarian setup
Squeeze score 62
elevated · 0–100
Fundamentals
Fair
Revenue growth +8%
Y/Y
Gross margin 35%
contracting
EPS growth −1%
Y/Y
Free cash flow $3.9B
Valuation P/E 95.3
rich
Buyback $2.3B
authorized
Balance sheet $18.6B
net debt
Quant / Vol
risk profile
Moderate
Volatility 26%
annualized · 1-yr
Max drawdown −24%
past year
ATR 2.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 4
Latest guidance · from the 8-K filed Nov 5, 2026
Adjusted Diluted EPS · full year fiscal 2027 Non-GAAP $13.10 – $13.30
Prior guidance period ended · from the Earnings Call filed Aug 6, 2026
Adjusted effective tax rate · full-year fiscal 26 16% – 17%
Adjusted EPS · full-year fiscal 26 $12.62 – $12.72
Guided vs delivered · last 4 settled
GAAP Revenues Fiscal 2025
guided $21.8B – $21.9B
$21.84B In line
Total FY 2024 Revenues Full Year FY 2024
guided $20.1B
$20.18B Beat +0.4%
Total FY 2023 Revenues from Continuing Operations Full Year FY2023
guided $19.3B
$19.37B Beat +0.4%
Fiscal year 2022 revenues fiscal year 2022
guided $18.75B – $18.83B
$18.87B Beat +0.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+27% Bullish
Price vs 50-day avg
+12% Bullish
RSI (14)
70 Neutral
MACD trend
Positive Bullish
52-week position
97% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $192 › 200d $169 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +164 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.98% of shares out · ▼ -9.0% MoM · 5.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1,501 holders — near 3-yr low, contrarian setup
Price context
position in its range since split · 2026-02-10
Range low $141 Now $215 · 97% Range high $218
vs 200-day avg +27% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted Diluted Earnings per Share from Continuing Operations non-GAAP $8.59 Nine Months Ended June 30, 2026 —
Free Cash Flow non-GAAP $1.73B Nine Months Ended June 30, 2026 —
Net Cash Provided by Continuing Operating Activities $2.1B Nine Months Ended June 30, 2026 —
Segment income as % of BioPharma Systems revenues 38.6% three months ended June 30, 2026 filing —
Segment income as % of Connected Care revenues 32.3% three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BDX
Becton Dickinson & Co
this stock
$58.68B — +8.2% 95.3 3.0%
ISRG
Intuitive Surgical Inc
$149.24B -24.0% +20.5% 52.2 2.0%
MDLN
Medline Inc.
$49.56B -10.3% +11.5% — 2.9%
ALC
Alcon Inc
$35.60B -6.0% +10.5% — 3.8%
RMD
Resmed Inc
$33.46B -1.3% +13.4% 21.7 7.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1,501
% held
93.6%
Net QoQ
-9.1M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
902
View
Short & Settlement
Short Interest Falling
Shares short
8.1M
Days to cover
5.2d
Change
-802.3K sh
View
Short Volume
Short vol %
58%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
495
Value
$98.2K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
41.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Thomas H. Kean
Amount
$1.0K–$15.0K
Traded
May 21, 2026
View
Financials
Financials
Revenue (FY)
$21.8B
Net income (FY)
$1.7B
EPS diluted
$4.58
View
Buybacks
Authorized · 2 programs
$2.3B
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 5, 2026
This year
23

Becton, Dickinson and Company reported FY26 revenue of $19.5 billion, up 4.9%, adjusted diluted EPS of $12.70, and fiscal 2027 adjusted diluted EPS guidance of $13.10 to $13.30.

View
Proposed Sales
Value
$626.1K
Shares
3.0K
Filed
Nov 5, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 10, 2026
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
BD Names Bridget Bagnato Worldwid…
Published
Nov 4, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
BDX +1.3% +11.2% +45.2% +8.9% +41.2%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +3.7% +15.9% +48.1% +11.9% +33.8%

Capital returns

Latest dividend
$1.05 / share · ex Sep 9, 2026
Declared · upcoming
$1.06 / share · ex Dec 10, 2026
Raised 27.2%
Paid (TTM)
$3.9755 / share · 4 payouts
Dividend yield (TTM, derived)
1.85%
Full dividend history
Buyback programs · 2 active · as of Jun 30, 2026
Authorized (total)
$2.25B
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 10795 CUSIP 075887109 13F (30d) 1416 filings 1306 filers Visit website Investor relations